Professor Ed Lavelle
Adjuvant Research
Journal articles (IF = impact factor)
Hughes, C.S., Colhoun, L.M., Bains, B., Burden, R.E., Burrows, J.F., Lavelle, E.C., Gilmore, B.F. and Scott, C.J. (2016, in press). Extracellular cathepsin S and intracellular caspase 1 activation are surrogate biomarkers of nanoparticle-induced lysosomal disruption in macrophages. Particle and fiber toxicology. (IF 7.1).
Schwartz, C., O’Grady, K., Lavelle, E.C. and Fallon, P.G. (2016). Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity - emerging roles in obesity, intestinal inflammation and cancer. European Journal of Immunology. doi: 10.1002/eji.201545780. (IF 4.0)
Lebre, F and Lavelle, E.C. (2016, in press). Modulation of immune and inflammatory responses by novel bio-materials. Advanced Materials. (IF 17.5).
Carroll, E.C., Jin, L., Mori, A., Munoz-Wolf, N., Oleszycka, E., Moran, H., Mansouri, S., McEntee, C., Lambe, E., Agger, E.M., Andersen, P., Cunningham, C., Hertzog, P., Fitzgerald, K.A., Bowie, A.G. and Lavelle, E.C. (2016). The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA sensor cGAS-STING-dependent Induction of Type I Interferons. Immunity 44, 1-12. IF 21.5)
Ní Cheallaigh, C., Sheedy, F.J., Harris, J., Munoz-Wolf, N., Lee, J., West, K., Palsson McDermott, E., Smyth, A., Gleeson, L.E., Coleman, M., Martinez, N., Hearnden, C.H.A., Tynan, G.A., Carroll, E., Jones, S.A., Corr, S.C., Bernard, N.J., Hughes,M., Corcoran,S., O’Sullivan, M., Fallon, C.M., Kornfeld, H., Golenbock, D., Gordon, S.V., O’Neill, L.A.J., *Lavelle, E.C. and *Keane, J (*joint senior authors) (2016). A common variant in Mal/TIRAP regulates interferon gamma signaling. Immunity 44, 2, 368-379. (IF 21.5)
Finlay, C.M., Stefanska, A.M., Walsh, K.P., Doyle, B., Boon, L., Lavelle, E.C.,Walsh, P.T. and Mills, K.H.G (2016). Helminth-induced IL-33 and IL-5 protects against autoimmunity. The Journal of Immunology. 196, 2, 703-14. (IF 4.9).
Oleszycka, E., Moran, H.B.T., Tynan, G.A., Hearnden, C.H., Coutts, G., Campbell, M., Allan, S.M., Scott, C.J. and Lavelle, E.C. (2016). IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. FEBS Journal. 283, 1, 9-24. (IF 4.0)
Brown, A.F., Murphy, A.G., Lalor, S.J., Leech, J.M., O’Keeffe, K.M., Mac Aogáin, M., O’Halloran, D.P., Lacey, K., Tavakol, M., Hearnden, C.H., Fitzgerald-Hughes, D., Humphreys, H., Fennell, J.P., van Wamel, W., Foster, T.J., Geoghegan, J.A., Lavelle, E.C., Rogers, T.R. and McLoughlin, R.M. (2015). Memory Th1 cells are protective in invasive Staphylococcus aureus infection. PloS Pathogens. 11(11):e1005226. (IF 7.6).
Davitt, C. and Lavelle, E.C. (2015). Delivery strategies to enhance oral vaccination against enteric infections. Advanced Drug Delivery Reviews. 91:52-69. (IF 15.0).
Kearney, C.J., Cullen, S.P., Tynan, G.A., Henry, C.M., Clancy, D., Lavelle, E.C. and Martin, S.J. (2015). Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production. Cell Death and Differentiation. doi: 10.1038/cdd.2014.222. (IF 8.4).
Abautret-Daly, A., Davitt, C. and Lavelle, E.C. (2014). Harnessing the antibacterial and immunological properties of mucosal-associated invariant T cells in the development of novel oral vaccines against enteric infections. Biochemical Pharmacology. 92, 2, 173-83. (IF 4.7).
Meraz, I.M., Hearnden, C.H.A., Liua, X., Yang, M., Williams, L., Gua, J., Rhudy, J.R., Yokoi, K., *Lavelle, E.C. and *Serda, R.E (joint senior authors). (2014). Multivalent presentation of MPL by porous silicon microparticles favors T helper 1 polarization increasing the anti-tumor efficacy of doxorubicin nanoliposomes. PLOS One. 9(4):e94703.(IF 3.2).
Doyle, S.L., Ozaki, E., Brennan, K., Humphries, M.M., Mulfaul, K., James Keaney, J., Kenna, P.F., Maminishkis, A., Kiang A-S., Saunders, S.P., Hams, E., Lavelle, E.C., Gardiner, C., Fallon, P.G., Adamson, P., Humphries, P. and Campbell, M (2014). IL-18 attenuates experimental choroidal neovascularization (CNV) representing a therapy for the prevention of wet age-related macular degeneration (AMD). Science Translational Medicine. 6, 230ra44. (IF 14,4)
Oleszycka, E. and Lavelle, E.C. (2014). The immunomodulatory properties of the vaccine adjuvant alum. Current Opinion in Immunology. 28C, 1-5. (IF 7.9).
Arancibia, S., Espinoza, C., Salazar, F., Del Campo, M., Tampe, R., Zhong, T-Y., De Ioannes, P., Moltedo, B., Ferreira, J., Lavelle, E.C., Manubens, A., De Ioannes, A.E. and Becker, M.I. (2014). A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata promotes potent anti-tumor activity in melanoma. PLOS One 9, 1:e87240. (IF 3.2).
Bourke J, Brereton CF, Gordon SV, Lavelle E.C. and Scanlan EM (2014). The Synthesis and Biological Evaluation of Mycobacterial p-Hydroxybenzoic Acid Derivatives (p-HBADs). Organic & Biomolecular Chemistry. 12,7, 1114-23. (IF 3.5).
Misstear, K., McNeela, E., Murphy, A.G., Geoghegan, J.A., O’Keeffe, K.M., Fox, J., Chan, K., Heuking, S., Collin, N., Foster, T.J., McLoughlin, R.M. and Lavelle, E.C. (2014). Targeted nasal vaccination provides antibody independent protection against Staphylococcus aureus. The Journal of Infectious Diseases. 209, 9, 1479-84. (IF 5.8).
Tynan, G.A., Hearnden, C.A., Oleszycka, E., Coutts, G., Jean O’Connell, J., Corrigan, M.A., Lynch, L., Campbell, M., Callanan, J.J., Mok, K.H., Geoghegan, J., O’Farrelly, C., Allan, S.M., O’Shea, D.B. and Lavelle, E.C. (2014). Endogenous oils derived from human adipocytes are potent adjuvants that promote IL-1α-dependent inflammation. Diabetes 63, 6, 2037-50. (IF 7.9).
Yang, M., Flavin, K., Kopf, I., Radics, G., Hearnden, C.H.A., McManus, G.J., Moran, B., Villalta-Cerdas, A., Echegoyen, L.A., Giordani, S. and Lavelle, E.C. (2013). Chemical surface functionalization of carbon nanoparticles modulates inflammatory cell recruitment and NLRP3 inflammasome activation. Small. 9(24):4194-206. (IF 8.4).
Maher, B., Wilk, M., Murphy, A., Geoghegan, J., Lavelle, E.C. and McLoughlin, R (2013). Nlrp-3 driven IL-17 production by γδT-cells controls infection outcomes during Staphylococcus aureus surgical site infection. Infection and Immunity. 81, 12, 4478-89. (IF 4.2).
Yang M, Hearnden, C.H, Oleszycka, E. and Lavelle, E.C. (2013). NLRP3 inflammasome activation and cytotoxicity induced by particulate adjuvants. Methods Mol Biol. 1040, 41-63. (IF 1.3).
Ruane, DT., Brane, L., Reis, B., Cheong, C., Poles, J., Do, Y., Zhu, H., Velinzon, K., Choi, J-H., Studt, N., Mayer, L., Lavelle, E.C., Steinman, R., Mucida, D and Mehandru, S. (2013). Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. The Journal of Experimental Medicine. 210, 9, 1871-88. (IF 13.9).
Ross, P.J., Sutton, C.E., Higgins, S., Allen, A.C., Walsh, K., Misiak, A., Lavelle, E.C., McLoughlin, R.M. and Mills KH (2013). Relative Contribution of Th1 and Th17 Cells in Adaptive Immunity to Bordetella pertussis: Towards the Rational Design of an Improved Acellular Pertussis Vaccine. PLoS Pathogens. 9, 4, e1003264. (IF 8.1).
Cullen, S.P., Henry, C.M., Kearney, C.J., Logue, S.E., Feoktiskova,M., Tynan, G.A., Lavelle, E.C., Leverkus, M. and Martin S.J. (2013). Fas/CD95-induced chemokines can serve as ‘Find-Me’ signals for apoptotic cells. Molecular Cell. 49(6):1034-48. (IF 14.5)
Kearney, C.J., Sheridan, C., Cullen, S.P., Tynan, G.A., Logue, S.E., Afonina, I.S., Vucic, D., Lavelle, E.C. and Martin, S.J. (2012). IAPs and their Antagonists Regulate Spontaneous and TNF-Induced Pro-Inflammatory Cytokine and Chemokine production. The Journal of Biological Chemistry. 288, 7, 4878-90. (IF 4.6).
Doyle, S.L., Campbell, M., Ozaki, E., Salomon, R.G., Mori, A., Kenna, P.F., Kiang, A-S., Humphries, MM., Lavelle, E.C., O’Neill, L., Hollyfield, J.G. and Humphries, P (2012). A protective role for NLRP3 in the development of age related macular degeneration, through the induction of IL-18, by endogenous drusen components. Nature Medicine. 18, 5, 791-798. (IF 24).
Peral de Castro, C., Jones, S.A., Ní Cheallaigh, C., Hearnden, C.A., Williams, L., Winter, J., Lavelle, E.C., Mills, K.H. and Harris, J. (2012). Autophagy Regulates IL-23 Secretion and Innate T Cell Responses through Effects on IL-1 Secretion. The Journal of Immunology. 189, 8, 4144-53.(IF 5.4).
Cunningham, C.C., Mills, E., Mielke, L.A., O'Farrell, L.K., Lavelle, E., Mori, A., McCarthy, G.M., Mills, K.H. and Dunne, A (2012). Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase. Clin Immunol. 144, 3, 228-36. (IF 4).
Mori, A., Oleszycka, E., Sharp, F.A., Coleman, M., Ozasa, Y., Singh, M., O’Hagan, D.T., Tajber, L., Corrigan, O.I. McNeela, EA. and Lavelle, E.C. (2012). The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses. The European Journal of Immunology. 42, 1-11. (IF 4.0).
Tynan, G.A., McNaughton, A., Jarnicki, A., Tsuji, T., and Lavelle, E.C. (2012). Polymyxin B inadequately quenches the effects of contaminating lipopolysaccharide on dendritic cells. PLoS One.7(5):e37261. (IF 4.5).
McNeela, E.A. and Lavelle, E.C. (2012). Recent advances in microparticles and nanoparticles for mucosal vaccination. Current Topics in Microbiology and Immunology. 354, 75-100. (IF 3.5).
Ruane, D.T. and Lavelle E.C. (2011) The role of CD103+ dendritic cells in the intestinal mucosal immune system. Frontiers in Immunology. 2:25. (IF 0 ).
Ni Cheallaigh, C., Keane, J., Lavelle, E.C., Hope, J. and Harris, J. (2011). Autophagy in the immune response to tuberculosis : clinical perspectives. Clinical and Experimental Immunology. 164, 3, 291-230. (IF 3.3).
Afonina, I.S., Tynan, G.A., Logue, S. E., Cullen, S.P., Bots, M., Lüthi, A.U., Reeves, E.P., McElvaney, N.G., Medema, J.P., Lavelle, E.C. and Martin, S.J. (2011). Granzyme B-dependent proteolysis acts as a switch to enhance the pro-inflammatory activity of IL-1. Molecular Cell. 44, 2, 265-278. (IF 14.5).
Schijns, V.E.J.C and Lavelle, E.C. (2011). Trends in vaccine adjuvants. Expert Review of Vaccines. 10, 4, 539-550. (IF 4.2).
McNaughton, A., McNeela, EA. and Lavelle, E.C. (2011). NLRP3 in protective immunity and vaccination against respiratory infection. Expert Review of Vaccines. 10, 3, 255-257. (IF 4.2)
Brereton, C.F., Sutton, C.E., Ross, P.J., Iwakura, Y., Pizza, M., Rappuoli, R., Lavelle, E.C. and Mills, K.H.G (2011). Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection via activation of IL-1 and IL-23. The Journal of Immunology. 186, 10, 5896-5906. (IF 4.9).
Harris, J..Hartman, M., Roche, C., Zeng, S.G., O’Shea, A., Sharp, F.A., Lambe, E.M., Creagh, E.M., Golenbock, D.T., Tschopp, J., Kornfeld, H., Fitzgerald, K.A. and Lavelle, E.C. (2011). Autophagy controls IL-1ß secretion by targeting pro-IL-1ß for degradation. The Journal of Biological Chemistry. 286, 11, 9587-9597. (IF 4.7).
McNeela, E., Burke, B., Neill, D., Baxter, C., Fernandes, V., Ferreira, D., Smeaton, S., El-Rachkidy, R., McLoughlin, R., Mori, A., Moran, B., Fitzgerald, K., Tschopp, J., Petrilli, V., Andrew, P., Kadioglu, A. and Lavelle, E.C. (2010). Pneumolysin Activates the NLRP3 Inflammasome and Promotes Proinflammatory Cytokines Independently of TLR4. PLos Pathogens 6(11):e1001191. (IF 8.1).
Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Franchi, , Yoshihara, E., Chen, Z., Mullooly, N., Mielke, L.A., Harris, J., Coll, R., Mills, K.H.G., Mok, K.H., Newsholme, P., Nuñez, G., Yodoi, J., Kahn, S.E., Lavelle, E.C. and O’Neill, L.A.J (2010). Activation of the Nlrp3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nature Immunology 11, 10, 897-904. (IF 20.0).
Lavelle, E.C., Murphy, C., O'Neill, L.A. and Creagh, E.M. (2010). The role of TLRs, NLRs and RLRs in mucosal innate immunity and homeostasis. Mucosal Immunology. 3, 1, 17-28. (IF 7.5)
Harris, J., Sharp, F.A. and Lavelle, E.C. (2010). The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. European Journal of Immunology 40, 3, 634-638. (IF 4.0).
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH (2010). Response: Characteristics of IL-17-Producing gammadelta T Cells. Immunity. 32, 1, 3-4. (IF 21.5).
Harris, J., Hope, J. and Lavelle, E.C. (2009). Autophagy and the immune response to TB. Transboundary and Emerging Diseases 56, 6-7, 248-254. (IF 3.1).
Lavelle, E.C., Thanavala, J. and Ogra, P. (2009) Mucosal immunity on the banks of the Duoro. Human Vaccines, 5, 5, 1-3. (IF 3.6).
Thanavala,Y., Lavelle, E.C. and Ogra, P. (2009) All things mucosal. Expert Reviews of Vaccines 8, 2, 139-142. (IF 4.2).
Brereton, C.F., Sutton, C.E., Lalor, S., Lavelle, E.C. and Mills, K.H.G. (2009). Inhibition of ERK MAP kinase suppresses IL-23 and IL-1 driven IL-17 production and attenuates autoimmune disease. The Journal of Immunology 183, 3, 1715-1723. (IF 4.9).
Sharp, F., Ruane, D., Claas, B., Creagh, E., Harris, J., Malyala, P., Singh, M., O’Hagan, D.T., Pétrilli, V., Tschopp, J., O’Neill, L.A.J. and Lavelle, E.C. (2009). Particulate vaccine adjuvants activate the NALP3 inflammasome. Proceedings of the National Academy of Sciences of the U.S.A. 106, 3, 870-875. (IF 9.7).
Sutton, C.E., Lalor, S.J., Sweeney, C.M., Brereton, C.F., Lavelle, E.C. and Mills, K.H.G (2009). IL-1β and IL-23 promote innate IL-17 production from gd T cells, which amplifies IL-17 production by CD4+ Th17 cells that mediate autoimmune inflammation. Immunity 31, 331-341. (IF 21.5).
Lüthi, A.U., Cullen, P.P., McNeela, E.A., Duriez, P.J., Afonina,I.S., Sheridan, C., Brumatti, G., Taylor, R.C., Kersse, K., Vandenabeele, P., Lavelle, E.C. and Martin, S.J (2009). Suppression of IL-33 Bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98. (IF 21,5).
Jarnicki, A.G., Conroy, H., Brereton, C., Donnelly, G., Toomey, D., Walsh, K., Sweeney, C., Leavy, O., Fletcher, J., Lavelle, E.C., Dunne, P. and Mills, K.H.G (2008). Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. The Journal of Immunology, 2008, 180: 3797-3806.(IF 4.9).
Lavelle, E.C. and O’Hagan, D.T. (2006). Delivery systems and adjuvants for oral vaccines. Expert Opinion on Drug Delivery 3, 6, 747-762. (IF 4.1).
Lavelle, E.C., Grant, G., Pfuller, U. and O’Hagan, D.T (2006). Type II ribosome-inactivating proteins from mistletoe are effective adjuvants when administered by mucosal and transcutaneous routes. Vaccine 24, Suppl 2:S2. (IF 3.6).
Higgins, S.H., Jarnicka, A., Lavelle, E.C. and Mills K.H.G. (2006). TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-23 and IL-1 driven IL-17-producing T cells. The Journal of Immunology 177, 11, 7980-7989.(IF 4.9).
Lavelle, E.C. (2006). Evaluation of the binding, uptake and immune responses elicited to orally administered lectins and microparticles. Methods 38, 2, 84-89. (IF 3.2).
Sutton, C., Keogh, B.K., Mills, K.H.G. and Lavelle, E.C. (2006). A crucial role for IL-1 in the induction of IL-17 producing T cells that mediate autoimmune encephalomyelitis. The Journal of Experimental Medicine 203, 7, 1685-1691. (IF 13.2).
Lavelle, E.C. (2005). Generation of improved mucosal vaccines by induction of innate immunity. Cellular and Molecular Life Sciences 62, 23, 2750-2770. (IF 5.9)
Armstrong, M.A., Lavelle, E.C., Loscher, C.E., Lynch, M.A. and Mills, K.H.G. (2005). Pro-inflammatory responses in the murine brain following intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in nasal vaccines. The Journal of Infectious Diseases 192, 9, 1628-1633. (IF 5.8).
Boyd, A.P., Ross, P.J., Conroy, H., Mahon, N., Lavelle, E.C. and Mills, K.H.G. (2005). Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. The Journal of Immunology 175, 730-738. (IF 4.9)
Lavelle, E.C., McGuirk, P. and Mills, K.H.G. (2004). Molecules of Infectious Agents as Immunomodulatory Drugs. Current Medicinal Chemistry 4, 5, 499-508. (IF 3.7).
Lavelle E.C., Grant, G., Pfuller, U. and O’Hagan, D.T. (2004). Immunological implications of the use of plant lectins for drug and vaccine targeting to the gastrointestinal tract. The Journal of Drug Targeting 12, 2, 89-95. (IF 2.7).
Lavelle, E.C., Jarnicki, A., McNeela, E., Armstrong, M., Higgins, S., Leavy, O. and Mills, K.H.G. (2004). Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. Journal of Leukocyte Biology 75, 5, 756-763. (IF 4.7)
*Bowe, F., *Lavelle, E.C., McNeela, E.A [*joint first authors]. Clare, S., Arico, B., Giuliani, M., Rae, A., Huett, A., Pizza, M., Rappuoli, R., Dougan, G. and Mills, K.H.G. (2004). A mucosal vaccine against group B Neisseria meningitides: Induction of bactericidal antibodies, secretory IgA, Th1 and Th2 responses following intranasal immunization with novel meningococcal antigens and mutants of E. coli heat labile enterotoxins. Infection and Immunity 72, 7, 4052-4060. (IF 4.2)
Ross, P.J., Lavelle, E.C., Mills, K.H.G. and Boyd, A.P. (2004). Adenylate cyclase toxin from Bordetella pertussis synergises with lipopolysaccharide to promote innate IL-10 production and enhances the induction of Th2 and regulatory T cells. Infection and Immunity 72, 3, 1568-1579. (IF 4.2).
Lavelle, E.C., McNeela, E., Armstrong, M., Leavy, O., Higgins, S.C. and Mills, K.H.G. (2003). Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. The Journal of Immunology 171, 2384-2392. (IF 4.9).
Higgins, S.C., Lavelle, E.C., McCann, C., Keogh, B., McNeela, E., Byrne, P., O’Gorman, B., Jarnicki, A., McGuirk, P. and Mills, K.H.G. (2003). Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. The Journal of Immunology 171, 3119-3127. (IF 4.9).
O’Hagan, D.T and Lavelle, E. (2002). Novel adjuvants and delivery systems for HIV vaccines. AIDS 2002: A year in review, 16, S115-S124. (IF 6.6, 14 citations).
Lavelle, E.C., Grant, G., Pusztai, A., Pfuller, U., Leavy, O., McNeela, E., Mills, K.H. and O'Hagan, D.T. (2002). Mistletoe lectins enhance immune responses to intranasally co-administered herpes simplex virus glycoprotein D2. Immunology 107, 268-274. (IF 3.7).
Lavelle, E.C. (2001). Targeted delivery of drugs to the gastrointestinal tract. CRC Critical ReviewsTM in Therapeutic Drug Carrier Systems 18, 4, 341-386. (IF 3.2).
Lavelle, E.C., Grant, G., Pusztai, A., Pfüller, U and O’Hagan, D.T. (2001). The identification of plant lectins with mucosal adjuvant activity. Immunology 102, 77-86. (IF 3.7).
Lavelle, E.C., Grant, G., Pusztai, A., Pfüller, U and O’Hagan, D.T. (2000). Mucosal immunogenicity of plant lectins in mice. Immunology 99, 1, 30-37. (IF 3.7).
Lavelle, E.C. (2000). Patent update on drug delivery: January-June (2000). Expert Opinion on Therapeutic Patents 10, 9,1335-1343. (IF 3.4).
Lavelle, E.C. (2000). Targeted mucosal delivery of drugs and vaccines. Expert Opinion on Therapeutic Patents 10, 2, 179-190. (IF 3.4).
Gill, I.J., Lin,W., Jenkins,P., Watts, P., Jiminez, M., Illum, L., Davis, S.S., Wood, J.M., Major, D., Minor, P.D., Li, X., Lavelle, E.C. and Coombes, A.G.A. (2000). Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine 18, 3-4, 238-250. (IF 3.6).
Lavelle, E.C., Yeh, M.K., Coombes, A.G.A. and Davis, S.S. (1999). The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine 17, 6, 512-529. (IF 3.6).
Delgado, A., Lavelle, E.C., Hartshorne, M. and Davis, S.S. (1999). PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Vaccine 12, 22, 2927-2938. (IF 3.6).
Coombes, A.G.A., Lavelle, E.C. and Davis, S.S. (1999). Biodegradable lamellar particles of poly (lactide) induce sustained immune responses to a single dose of adsorbed protein. Vaccine 17, 19, 2410-2422. (IF 3.6).
Takahata, H., Lavelle, E.C., Coombes, A.G.A., Rafati, H. and Davis, S.S. (1998). An investigation into the effects of exposure to digestive enzymes and polymer degradation on the integrity of microparticle-associated antigen. Journal of Controlled Release 50, 1-3, 237-248. (IF 7.7).
Coombes, A.G.A., Yeh, M-K., Lavelle, E.C. and Davis, S.S. (1998). The control of protein release from poly (DL lactide-co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. Journal of Controlled Release 52, 311-320. (IF 7.7)
Lavelle, E.C., Jenkins, P.G. and Harris, J.E. (1997). Oral immunisation of rainbow trout with antigen microencapsulated in PLG microparticles. Vaccine 15, 10, 1070-1078. (IF 3.6).
Lavelle, E. C. and Harris, J. E. (1997). The proteolysis of an orally administered protein antigen in the digestive tract of rainbow trout, Oncorhynchus mykiss (Walbaum,1792). Comparative Biochemistry and Physiology. 117A, 2, 263-275. (IF 2.4).
Rafati, H., Lavelle, E.C., Coombes, A.G.A., Stolnik, S., Holland, J. and Davis, S.S. (1997). The immune response to antigen associated with microparticles prepared using different surfactants. Vaccine. 15, 17-18, 1888-1897. (IF 3.6).
Coombes, A.G.A., Lavelle, E.C., Jenkins, P. G. and Davis, S. S. (1996). Single dose, polymeric, microparticulate vaccine delivery systems: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine. 14, 1429-1438. (IF 3.6).
Thomas, N. W., Jenkins, P.G., Howard, K.A., Smith, M.W., Lavelle, E.C., Holland, J. and Davis, S.S. (1996). Particle uptake and translocation across epithelial membranes. The Journal of Anatomy. 189, 487-490. (IF 2.4).
Lavelle, E.C., Sharif, S., Thomas, N. W., Holland, J. and Davis, S.S. (1995). The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Advanced Drug Delivery Reviews. 18, 5-22. (IF 15.0).
Jenkins, P.G., Barton, R.N., Harris, J.E., Lavelle, E.C. and Wrathmell, A.B. (1992). Enhanced delivery systems for enteric antigen uptake in teleosts. Vaccine. 10, 281-282. (IF 3.6).
Book chapters
Muñoz-Wolf, N and Lavelle, E.C. (2016, in press). Innate immune receptors in Nod Like Receptors; Methods in Molecular Biology, Springer. Editors: Pablo Pelegrin and Francesco Di Virgilio. ISBN 978-1-4939-3564-2.
Hearnden, C and Lavelle, E.C. (2013). Chapter 21. Adjuvant Strategies in Vaccines. Page 333-349 in Prendergast/Jaffee: Cancer Immunotherapy: Immune Suppression and Tumor Growth, Second Edition. Academic Press. ISBN 978-0-12-394296-8.
McEntee, C., Lavelle, E.C. and O’Hagan, D.T (2015). Chapter 63. Antigen Delivery Systems I: Nonliving Microparticles, Liposomes, and Immune-Stimulating Complexes (ISCOMs). Pages 1211-1231. In J Mestecky et al (Eds): Handbook of Mucosal Immunology 4th Edition. ISBN: 978-0-12-415847-4.
Sharp, F.A. and Lavelle, E.C. (2013). Encyclopedia of Pharmaceutical Science and Technology, Fourth Edition (Online), edited by James Swarbrick. Taylor and Francis LLC. July 1, 2013 by CRC Press. Reference-4296. ISBN 9781841848198 - CAT# H100233
Sharp, F.A. and Lavelle, E.C. Immunostimulatory properties of biodegradable microparticles. in Vaccinology: Principles and Practice. Wiley-Blackwell. John Morrow, Ed. Hardcover: 452 pages, Publisher: Wiley-Blackwell (May 25 2012) ISBN-10: 1405185740. ISBN-13: 978-1405185745.
Schijns, V.E.J.C. and Lavelle, E.C. (2011, in press). Chapter 9; Future Trends of Novel Vaccine Adjuvants in Novel Immunologic Adjuvants, Future Science Group e book, Duc Hong Le, Editor
Schijns, V.E.J.C. and Lavelle, E.C. (2011, in press). Chapter 1; Rationales for including adjuvants in vaccines in Novel Immunologic Adjuvants, Future Science Group e book. Duc Hong Le, Editor.
Sharp, F. and Lavelle, E.C. (2011). Discovery of vaccine adjuvants. In Development of therapeutic agents handbook. Volume 8 of Pharmaceutical development series. Editors Shane, Cox, Gad. John Wiley & Sons. ISBN 0471213853, 9780471213857. 1216 pages.
Lavelle, E.C. and O'Hagan, D.T. Oral delivery of vaccines. In Oral Peptide and Protein Drug Delivery. (Ed, J Fix. and V H.L. Lee).Marcel Dekker, New York (submitted).
Lavelle E.C., Leavy O. Mills KHG. Modified bacterial toxins. In Vaccine Adjuvants: Immunological and Clinical Principles. (Ed C.J. Hackett) Humanu Press). Editors Charles J Hackett & Donald A Harn Jr, ISBN: 0-89603-892-0, Publisher Humana, Pub. Date: December 2005. Pages: 296
Lavelle, E.C. (1999). Lectins in oral vaccination. In COST 98-Effects of antinutrients on the nutritional value of legume diets. Volume 6 (Eds, S. Bardocz., G. Hajós and A. Pusztai). pp 148-159. European Commission.